Results 141 to 150 of about 39,316 (219)

Multiple Myeloma Presenting as Lower Gastrointestinal Bleeding: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Multiple myeloma (MM) is a malignant hematologic neoplasm that primarily affects the bone marrow and can invade other organs, leading to diverse clinical manifestations. Presentation with gastrointestinal bleeding as the initial symptom is exceptionally rare.
Ahmed Arabi, Naseem Ambra, Asgad Mohamed Ahmed Eltigani, Asma Ahmed Yousif, Abdelkarim Hashim Mohamed   +4 more
wiley   +1 more source

The Ubiquitin Ligase Zinc Finger SWIM Domain‐Containing Protein 8 Regulates Oligodendrocyte Development Through the Argonaute2/MicroRNA‐7 Axis

Glia, Volume 74, Issue 5, May 2026.
ZSWIM8, an E3 ubiquitin ligase that broadly targets IDR‐rich proteins, drives MiR‐7‐dependent AGO2 degradation and the turnover of many RBPs. Loss of ZSWIM8 leads to MiR‐7 accumulation in oligodendrocyte progenitor cells and myelination defects in the developing brain. ABSTRACT Proteostasis of proteins with intrinsically disordered regions (IDRs) is of
Jing Lei, Siming Zhong, Rong Fan, Xin Shu, Guan Wang, Jiansheng Guo, Shuting Xue, Luqian Zheng, Aiming Ren, Junfang Ji, Bing Yang, Shumin Duan, Zhiping Wang, Xing Guo   +13 more
wiley   +1 more source

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT Oligo‐secretory and non‐secretory MM present a clinical challenge due to the difficulties in initial diagnosis, response to treatment assessment, and relapse detection. They are excluded from most clinical trials, which typically require measurable disease.
Iuliana Vaxman, Itai Zamir, Inbar Cohen, Gil Fridberg, Tamir Shragai, Svetlana Trestman, Tomer Ziv Baran, Efrat Luttwak, Ronit Shmuel, Natan Melamed, Shai Levy, Irit Avivi, Pia Raanani, Angela Dispenzieri, Morie A. Gertz, Yael C. Cohen   +15 more
wiley   +1 more source

Mechanisms of action and clinical development of elotuzumab [PDF]

, 2017
Colonna, Marco, Ritchie, David
core   +2 more sources

Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 5, May 2026.
Hetrombopag targeted PNPO to inhibit multiple myeloma. ABSTRACT Multiple myeloma (MM) is a malignancy of plasma cells whose excessive immunoglobulin production elevates reactive oxygen species (ROS), promoting pathogenesis. Active compounds from Traditional Chinese Medicine, such as celastrol, can exert antitumour effects by further increasing ROS ...
Tianyi Yu, Cheng Wang, Jingru Xie, Yongxin Wei, Hongwei Cui, Huaxia Zhang, Fan Zhou, Zhendong Deng, Ye Yang, Chunyan Gu   +9 more
wiley   +1 more source

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: Application of a novel pharmacodynamic assay [PDF]

, 2016
et al,, Vij, Ravi
core   +2 more sources

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment

European Journal of Haematology, Volume 116, Issue 5, Page 577-584, May 2026.
ABSTRACT Background Severe renal insufficiency requiring dialysis in newly diagnosed multiple myeloma (NDMM) patients has been independently associated with poor survival outcomes. However, there is a paucity of data on factors predicting renal recovery and survival outcomes of these patients.
Rintu Sharma, Eshetu G. Atenafu, Esther Masih‐Khan, Harjot Vohra, Sita Bhella, Christine Chen, Vishal Kukreti, Guido Lancman, Anca Prica, A. Keith Stewart, Rodger Tiedemann, Suzanne Trudel, Chloe Yang, Donna Reece   +13 more
wiley   +1 more source

Real-world drug regimes for multiple myeloma in a Swiss population (2012 to 2017) : cost-outcome description [PDF]

, 2019
Blozik, Eva, Eichler, Klaus, Rapold, Ronald, Reich, Oliver, Wieser, Simon   +4 more
core   +1 more source

Targeting PRKCN, an Essential Driver Orchestrating mTOR‐IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma

Advanced Science, Volume 13, Issue 21, 13 April 2026.
Constitutive PRKCN expression is driven by super‐enhancers and modulated by NF‐κB signaling in multiple myeloma (MM). PRKCN activates mTORC1/2‐IRF4 signaling axis and favors tumor cell growth independently of its kinase activity. IRF4 reciprocally promotes PRKCN transcription, creating a feed‐forward loop.
Koukou Tang, Dongpeng Jiang, Peng Ke, Xiaosen Bian, Lili Zhang, Ying Zhang, Tingting Zhu, Weiwei Qu, Wenhui Qi, Yang Xu, Chengcheng Fu, Depei Wu, Jianhong Chu   +12 more
wiley   +1 more source

Mapping CSC‐Mediated Ovarian Cancer Chemoresistance via CXCR4‐PET to Guide Precision Cisplatin Re‐Sensitization Therapy

Advanced Science, Volume 13, Issue 19, 2 April 2026.
CXCR4 functions as a potential cancer stem cell‐associated marker linked to chemoresistance in ovarian cancer, and an inhibitor of CXCR4, AMD3100, can enhance the cytotoxic response to cisplatin. Based on these findings, [68Ga]Ga‐Pentixafor positron emission tomography enables selective visualization of CXCR4‐high ovarian cancer, while AMD3100 combined
Lixia Feng, Simei Zhao, Zheng Wei, Wenwen Wang, Feiquan Ying, Lin Huang, Mengna Zhu, Mengqing Chen, Qiang Yang, Si Sun, Dawei Jiang, Lingling Gao, Jing Cai   +12 more
wiley   +1 more source